Back

Artelo Biosciences shares surge over 200% after obesity treatment patent filing

Verifying
  • Artelo Biosciences announced a provisional patent application covering obesity candidate ART27.13.
  • ART27.13 combined with semaglutide reduced obese mice's body weight by approximately 40%.
  • ARTL shares remained 59% below their year-to-date opening price after Wednesday's rally.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.